330 related articles for article (PubMed ID: 31676541)
1. ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications.
Armstrong SA; Schultz CW; Azimi-Sadjadi A; Brody JR; Pishvaian MJ
Mol Cancer Ther; 2019 Nov; 18(11):1899-1908. PubMed ID: 31676541
[TBL] [Abstract][Full Text] [Related]
2. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer.
Gout J; Perkhofer L; Morawe M; Arnold F; Ihle M; Biber S; Lange S; Roger E; Kraus JM; Stifter K; Hahn SA; Zamperone A; Engleitner T; Müller M; Walter K; Rodriguez-Aznar E; Sainz B; Hermann PC; Hessmann E; Müller S; Azoitei N; Lechel A; Liebau S; Wagner M; Simeone DM; Kestler HA; Seufferlein T; Wiesmüller L; Rad R; Frappart PO; Kleger A
Gut; 2021 Apr; 70(4):743-760. PubMed ID: 32873698
[TBL] [Abstract][Full Text] [Related]
3. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
[TBL] [Abstract][Full Text] [Related]
4. ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage.
Perkhofer L; Schmitt A; Romero Carrasco MC; Ihle M; Hampp S; Ruess DA; Hessmann E; Russell R; Lechel A; Azoitei N; Lin Q; Liebau S; Hohwieler M; Bohnenberger H; Lesina M; Algül H; Gieldon L; Schröck E; Gaedcke J; Wagner M; Wiesmüller L; Sipos B; Seufferlein T; Reinhardt HC; Frappart PO; Kleger A
Cancer Res; 2017 Oct; 77(20):5576-5590. PubMed ID: 28790064
[TBL] [Abstract][Full Text] [Related]
5. Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma.
Schmitt A; Feldmann G; Zander T; Reinhardt HC
Oncol Res Treat; 2018; 41(10):619-625. PubMed ID: 30286473
[TBL] [Abstract][Full Text] [Related]
6.
Nanda N; Roberts NJ
Genes (Basel); 2020 Jan; 11(1):. PubMed ID: 31963441
[TBL] [Abstract][Full Text] [Related]
7. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
Das S; Cardin D
Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
[TBL] [Abstract][Full Text] [Related]
8. The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma.
Shui L; Li X; Peng Y; Tian J; Li S; He D; Li A; Tian B; Li M; Gao H; An N; Yi C; Cao D
J Transl Med; 2021 Jul; 19(1):301. PubMed ID: 34247626
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic
Hannan Z; Yu S; Domchek S; Mamtani R; Reiss KA
JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33733050
[TBL] [Abstract][Full Text] [Related]
10. Targeting DNA damage repair pathways in pancreas cancer.
Crowley F; Park W; O'Reilly EM
Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
[TBL] [Abstract][Full Text] [Related]
11. ATM- and ATR-induced primary ciliogenesis promotes cisplatin resistance in pancreatic ductal adenocarcinoma.
Chao YY; Huang BM; Peng IC; Lee PR; Lai YS; Chiu WT; Lin YS; Lin SC; Chang JH; Chen PS; Tsai SJ; Wang CY
J Cell Physiol; 2022 Dec; 237(12):4487-4503. PubMed ID: 36251015
[TBL] [Abstract][Full Text] [Related]
12. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
[TBL] [Abstract][Full Text] [Related]
13. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
Cui Y; Palii SS; Innes CL; Paules RS
Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
[TBL] [Abstract][Full Text] [Related]
14. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma.
Xie F; Ding D; Lin C; Cunningham D; Wright M; Javed AA; Azad N; Lee V; Donehower R; De Jesus-Acosta A; Le DT; Pishvaian M; Shin EJ; Lennon AM; Khashab M; Singh V; Klein AP; Roberts NJ; Hacker-Prietz A; McPhaul T; Burkhart RA; Burns WR; Narang A; Zaheer A; Fishman EK; Thompson ED; Anders R; Yu J; He J; Wolfgang CL; Zheng L; Liu D; Wu K; Laheru DA
JCO Precis Oncol; 2022 Jun; 6():e2100404. PubMed ID: 35737913
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of ATM-deficient pancreatic cancer cells to radiation.
Ayars M; Eshleman J; Goggins M
Cell Cycle; 2017 May; 16(10):991-998. PubMed ID: 28453388
[TBL] [Abstract][Full Text] [Related]
16. ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer.
Drosos Y; Escobar D; Chiang MY; Roys K; Valentine V; Valentine MB; Rehg JE; Sahai V; Begley LA; Ye J; Paul L; McKinnon PJ; Sosa-Pineda B
Sci Rep; 2017 Sep; 7(1):11144. PubMed ID: 28894253
[TBL] [Abstract][Full Text] [Related]
17. OCIAD1 promoted pancreatic ductal adenocarcinoma migration by regulating ATM.
Ji W; Zheng K; Song B; Qin A; Chandoo A; Shao Z; Bi J; Yang X; Jin G; Shen X
Pancreatology; 2019 Jul; 19(5):751-759. PubMed ID: 31221523
[TBL] [Abstract][Full Text] [Related]
18. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
19. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.
Peters ML; Tseng JF; Miksad RA
Clin Ther; 2016 Jul; 38(7):1622-35. PubMed ID: 27041411
[TBL] [Abstract][Full Text] [Related]
20. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
Cancer Treat Rev; 2021 Nov; 100():102262. PubMed ID: 34418781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]